Actively Recruiting

Age: 18Years - 85Years
All Genders
ID04664465

PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS in Inflammatory Rheumatic Diseases

Led by University Hospital, Brest · Updated on 2025-02-11

300

Participants Needed

11

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying patients with inflammatory rheumatic diseases who need long-term glucocorticoid therapy to find factors that predict the risk of serious complications from this treatment. The goal is to create a tool that can estimate the chance of developing these complications within one year, which could help doctors choose the best initial treatments for patients in daily care and future studies. This observational study involves patients starting or restarting glucocorticoid treatment at doses of 15 mg/day or higher, planned for more than three months. There are no experimental drugs or procedures; instead, participants are monitored to collect routine clinical data, biological tests, and bone density scans (DXA) at the beginning of treatment. Participants will be followed for one year to observe any clinically important complications related to glucocorticoid use. Researchers will assess quality of life using the SF-36 questionnaire and monitor safety and health status. The study aims to develop a predictive score based on these observations, with total participation lasting one year.

CONDITIONS

Brief Title

PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Life expectancy > 1 year
  • Need to start prolonged glucocorticoid therapy at a dose of 15 mg/day or higher for an inflammatory rheumatic disease
  • Starting treatment or experiencing a relapse
  • Planned glucocorticoid treatment duration longer than 3 months
Not Eligible

You will not qualify if you...

  • Unable to give consent
  • Previous corticosteroid therapy at more than 5 mg per day within the last 3 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 1 year

Participants who undergo routine care with prolonged glucocorticoid therapy are observed to assess complications and quality of life outcomes.

Regular assessments during treatment period

Trial Site Locations

Total: 11 locations

1

CHU d'Angers

Angers, France, 49933

Actively Recruiting

2

CHRU de Brest

Brest, France, 29609

Actively Recruiting

3

CHD Vendée

La Roche-sur-Yon, France, 85925

Actively Recruiting

4

CH Le Mans

Le Mans, France, 72000

Actively Recruiting

5

CH des Pays de Morlaix

Morlaix, France, 29672

Actively Recruiting

6

CHU de Nantes

Nantes, France, 44093

Actively Recruiting

7

CHR d'Orléans

Orléans, France, 45067

Not Yet Recruiting

8

<CHU de Poitiers

Poitiers, France

Actively Recruiting

9

CHIC Quimper

Quimper, France, 29000

Actively Recruiting

10

Clinique St Exupéry

Toulouse, France

Actively Recruiting

11

CHU de Tours

Tours, France, 37044

Actively Recruiting

Loading map...

Research Team

D

Dewi GUELLEC

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

Cross-over, Randomized, Open-label, Single-centre, Phase II ...

Giant Cell Arteritis

Actively Recruiting

1 location

A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Recepto...

Systemic Sclerosis

Actively Recruiting

17 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here